Agenda Day 1

BioData West: Day 1

08:30

Chairman's Opening Remarks

Mathai Mammen
08:40

J&J FUTURE VISION IN AI AND COMPUTATIONAL BIOLOGY

Atul Butte
09:00

Rare Diseases - Bringing big data and genomics to unlock cures

  • What is the current state of the field and how have new techniques in data analytics allowed us to probe deeper into data sets to gain understanding of rare disease morphologies?
  • How do we connect millions of disease specific data points using novel statistical machine learning techniques to develop new therapies? 
  • The time is now - how does UCSF leverage the power of supercomputing infrastructure, once reserved for astrophysicists, to develop new pathways to cures? 
Panel discussion
10:00

PLATINUM SPONSORSHIP AVAILABLE

PLATINUM SPONSORSHIP AVAILABLE
Do you have a solution you would like to share with our audience?
Contact Michael Shackil now on: michael.shackil@terrapinn.com  or call at +1 646.619.1809
 
10:20

Speed Networking


 
10:40

Morning Coffee


 

GENOMICS & HEALTH

PRECISION MEDICINE

ARTIFICIAL INTELLIGENCE

GENOMICS & HEALTH
11:20

Developing “DAVE”: a simple way to visualize large datasets in the battle against cancer

  • How new tools and platforms developed by the NCI are changing the paradigm of data accessibility across the country
  • How these tools allow us to keep up with the exponential worldwide growth of genomic datasets
  • How to carry out complex analysis at the data source whilst allowing the user to explore the data and download the desired facets
PRECISION MEDICINE
11:20

Using different whole genome sequencing platforms to characterize cancer genomes and their clinical impact

  • How do we balance the equation of Speed: Depth: Cost across genomic sequencing options
  • Covering Illumina and high throughput whole genome sequencing including mate-pair sequencing
  • What is the impact of BGI’s proposed $100 whole genome on the clinician and what is the value add to preemptive care?
ARTIFICIAL INTELLIGENCE
11:20

Augmenting Drug Discovery with Artificial Intelligence at Massive Scale

  • Bringing substantial improvements to the efficiency of discovery and development efforts through the expansion and acceleration of traditional approaches
  • How Recursion views the use of AI in discovery and development – from strategies to accelerate discovery and imaged-based phenotypic screening platforms 
  • Overviews of internal successes in rare disease, immunology, and immuno-oncology  alongside partnerships with large pharmaceutical companies including Sanofi and Takeda
  • Recursion’s 5-7 year vision to leverage technology and massive proprietary datasets to build a map of human cellular biology 
GENOMICS & HEALTH
11:40

New analytical tools for OMICS How to get the best out of your data!

  • Tackling the new emerging field of integrating disparate omic data from genomics, proteomics andglycomics
  • Identifying the technical and biological barriers to omic integration, with solutions to build a consensus towards data integration in bioscience and better defined phenotypes
  • What is being done to facilitate the integration effort in an effective manner?
PRECISION MEDICINE
11:40

Integrating gene panels and EMR records to develop treatment pathways and cancer cure frameworks on large scales

  • What impacts will the expansion of the Swedish Precision medicine program have on healthcare across the system?
  • Implementing new technologies -  How we are implementing the roadmap for the delivery of next generation precision medicine into the Providence Health System?
  • What evidence is there for universal genetic testing of cancer patients and will it bring the expected value?
ARTIFICIAL INTELLIGENCE
11:40

Rethinking predictive modelling in the age of AI

  • How Numerate’s platform drives programs by following signals and unlocking low through-put / high content biology 
  • Applying similar modeling techniques with publicly available data in order to successfully model a vast number of sources of preclinical attrition (ADME and tox)
  • Why pharma and health systems need to start sharing data to guarantee the success of predictive modelling 
Brandon Allgood, Chief Technology Officer, Numerate Inc
GENOMICS & HEALTH
12:00

SPONSORSHIP AVAILABLE

Do you have a solution you would like to share with our audience?
Contact Michael Shackil now on: michael.shackil@terrapinn.com  or call at +1 646.619.1809
PRECISION MEDICINE
12:00

SPONSORSHIP AVAILABLE

Do you have a solution you would like to share with our audience?
Contact Michael Shackil now on: michael.shackil@terrapinn.com  or call at +1 646.619.1809
ARTIFICIAL INTELLIGENCE
12:00

Extracting precise biodata through the power of text mining

  • Empowering high-value knowledge discovery and decision support
  • Improving risk stratification through the characterization of patient populations based on social determinant data
  • Supporting clinical document improvement through NLP
round tables
12:20

INTERACTIVE E ROUNDTABLES

        1) Integrating EMR - Integration of electronic medical records with a biomedical knowledge network to predict medical outcomes
Chair: Sergio Baranzini, Professor UCSF

        2)  Collaboration - How to enable researchers to use data and collaborate easier?
Chair: Christopher Riley, Research Administration Manager, The Institute for Precision Cardiovascular Medicine

       3) Quantum Computing -  Where are we and what we are doing?
Chair: Handol Kim, General Manager, Quadrant Machine Learning Business Unit, D-Wave Systems, Inc

       4) CLSA California - Partnering and driving a hot bed of translational medicine in California
Chair: Sara Radcliff, President and Chief Executive Officer, California Life Sciences Association

       5) Electronic Consent - How to develop an electronic e-trial strategy effectively?
Chair: Megan Doerr, Principal Scientist, Sage Bionetworks
Sarah Meeder, Research Compliance Specialist, CUNY

       6) Personal Genetic Testing - What are the impacts and implications?
Chair: Westyn Branch-Elliman, Instructor in Medicine, Harvard Medical School
      
       7) Drug Discovery - Expediting the drug development through genomics, structural and cultural changes 
Chair: Nadeem Sarwar, President, AiM Institute, Eisai
          
       8) Big Data and the CNS - using big data datasets and approaches in the development of medicines for CNS indications including NDDs and pain/migraine disorders
Chair: Michael Burczynski, Senior Director and Head of Translational Biomarker Research, Early Stage Development, Teva

       9) Stem Cells & Rare Disseises - How to develop an infrastructure in which researchers can be connected with patients and tools to develop therapies

     10) Text mining and Image Recognition - Developing new tools
Chair: Karim Galil, CEO, Mendel Health

     11) Scientific Software- Enabling research at Verily
Chair: Mauricio Carneiro, Head of Scientific Software, Verily (Google Life Sciences)

     12) Standards in Genetic Testing – Setting the benchmark in quality data sets
Chair: Robert Burton, Founder and CEO, Center for Genomic Interpretation
 
  • Big Data and the CNS - using big data datasets and approaches in the development of medicines for CNS indications including NDDs and pain/migraine disorders
  • Michael Burczynski

    Moderator:
    Michael Burczynski, Executive Director, Head Of Integrated Clinical Biomarker Technologies, Bristol-Myers Squibb

  • CLSA California: Partnering and driving a hot bed of translational medicine in California
  • Sara Radcliffe

    Sara Radcliffe, President and Chief Executive Officer, California Life Science Association

  • Collaboration: How to enable researchers to use data and collaborate easier?
  • Chris Riley

    Chris Riley, Research Manager- Institute for Precision Cardiovascular Medicine, American Heart Association

  • Drug Discovery - Expediting the drug development through genomics, structural and cultural changes
  • Nadeem Sarwar

    Nadeem Sarwar, President AiM Institute, Eisai

  • Electronic Consent - How to develop an electronic e-trial strategy effectively?
  • Sarah Meeder

    Sarah Meeder, Research Compliance Specialist, C.U.N.Y. York College

  • Integrating EMR: Integration of electronic medical records with a biomedical knowledge network to predict medical outcomes
  • Sergio Baranzini

    Sergio Baranzini, Professor, UCSF

  • Personal genetic testing - What are the impacts and implications?
  • Westyn Branch-Elliman

    Westyn Branch-Elliman, Instructor in Medicine, Harvard Medical School

  • Quantum Computing: Where are we and what we are doing?
  • Handol Kim

    Handol Kim, Sr. Director, Quadrant Machine Learning BU, D-Wave Systems

  • Standards in genetic testing – Setting the benchmark in quality data sets
  • Robert Burton

    Robert Burton, Co-founder and President, Center for Genomic Interpretation

  • Stem cells & Rate Disseises - How to develop an infrastructure in which researchers can be connected with patients and tools to develop therapies
  • Text mining and image recognition - Developing new tools
  • GENOMICS & HEALTH
    14:20

    Understanding the new blockchain ecosystem - empowering research and data democratization in a secure manner

    • Improve drug traceability between drug manufacturers, wholesalers, pharmacists and patients through tracking and verification of secure product information 
    • Improving authentication of health records and protocols on record sharing 
    • Empowering clinical trials where altering or modifying data from clinical trials fraudulently can be eradicated 
    • Precision medicine -  where patients, researchers and providers can collaborate to develop individualised care
    PRECISION MEDICINE
    14:20

    Risk management for precision medicine and big bioda

    • How to implement a risk mitigation process amongst a complex healthcare system
    • Essential parts of the risk management program and case studies on they were implemented at Lifespan
    • What are the advantages of systematic frameworks to identifying, assessing, and addressing risks in the implementation of precision medicine?
    ARTIFICIAL INTELLIGENCE
    14:20

    A computational approach for identifying synergistic drug combinations- fuelling a new generation of drug combinations to treat cancers

    • Identification of the right combinations through trial and error, a labor and resource intensive process whose scale quickly escalates as more drugs can be combined
    • Engaging in the development of a broad computational approach for predicting synergistic combinations using easily obtainable single drug efficacy.
    • How does this allow you to forego a detailed mechanistic understanding of drug function, and limited drug combination testing?
    • Why is this method impactful for identification of drug synergy to drive new effective cancer cures into the clinic?
    GENOMICS & HEALTH
    14:40

    Blockchain: how to make it work for emerging and less-developed healthcare systems

    • Exploring options using blockchain to achieve better health data storage and applications 
    • Discussing clinical data access, exchange, interoperability, privacy issues and regulatory concerns
    • How applications for pharma focus on aging and longevity research, which could enable Africa to make more original contributions to healthcare
    • How optimizing processes for emerging and less-developed healthcare systems like in Africa could be helpful in the acceleration of progress for more developed healthcare systems 
    PRECISION MEDICINE
    14:40

    California’s Initiative to advance Precision Medicine from the bench to the bedside –

    • Hear how the Governor of California’s interest and leadership in the field led to statewide collaborative models to realize the potential of precision medicine 
    • How the state established multi-sector collaborative teams to advance efforts in precision medicine
    • Examples from the eight demonstration projects that range from heart disease to pediatric cancer
    ARTIFICIAL INTELLIGENCE
    14:40

    Novel CNS drug targets in the regulome identified by deep learning

    • How to use domain expert knowledge-driven deep learning of pharmaco-phenomic datasets to yield abundant human CNS drug targets
    • Moving beyond the known "reader, writer and eraser" proteins: using computational methodologies to identify more selective candidates
    • Utilizing a spatial, longitudinal and biomechanical dynamical analysis of the output to reveal previously unknown network-based drug targets
    GENOMICS & HEALTH
    15:00

    SPONSORSHIP AVAILABLE

    Do you have a solution you would like to share with our audience?
    Contact Michael Shackil now on: michael.shackil@terrapinn.com  or call at +1 646.619.1809
    PRECISION MEDICINE
    15:00

    SPONSORSHIP AVAILABLE

    Do you have a solution you would like to share with our audience?
    Contact Michael Shackil now on: michael.shackil@terrapinn.com  or call at +1 646.619.1809
    GENOMICS & HEALTH
    15:20

    Computational identification of isoform switch and alternative splicing events in ZSF1 fa/faCP rats, a model of human type 2 diabetes: How new isoform technologies could transform research and healthc

    • Identification of predictive biomarkers of disease progression using isoform level sequencing- what are the potential implications for the clinic?
    • Why are we not moving to isoform level resolution that could provide us with real biological insights? 
    • With a greater understanding of isoform switching we can remove the chance of false signals for cancer states - how significant is isoform level sequencing in removing signal noise? 
    PRECISION MEDICINE
    15:20

    Developing new drug targets for aging through novel insilico methodologies

    • Aging has become a major risk factor for many diseases including cancer, diabetes, heart disease and dementia
    • Defining new tools for the applications of aging research and information technology 
    • Empowering new business models, regulation, comprehensive and integrated set of aging biomarkers 
    • New engagements with large pharmaceutical companies and investors to fully drive the field forwards
    ARTIFICIAL INTELLIGENCE
    15:20

    Multimodel data analysis for single cell multiuse data for immunotherapy

    • Predictive biomarkers for ovarian and liver cancer developed through novel self-leaning algorithms to provide actionable cures
    • How to translate an equation into a cure in less than a year using new algorithms
    • Predicting response to blockade to specific immune checkpoint genes
    • Multimodel data analysis for biomarker discovery
    GENOMICS & HEALTH
    15:40

    Systems biology approaches to determine the cell-specific gene regulatory potential of genetic associations in complex diseases

    • Genetic association studies identify risk DNA variants but fall short of providing a biological context
    • How UCSFe integrated GWAS data with regulatory information from ENCODE and REP and built cell-specific biological risk networks
    • How UCSF employed this approach to create individualized cell-specific risk networks to characterize risk in more than 2000 patients   
    PRECISION MEDICINE
    15:40

    Molecular signatures of human mortality: biomarkers and therapies

    • Accelerating drug testing by developing molecular signatures of mortality
    • Attaining the best signatures by deeply phenotyping large human cohorts 
    • High-throughput omics data, coupled with innovative machine learning, is revealing new biomarkers and drug targets
    ARTIFICIAL INTELLIGENCE
    15:40

    Fuelling R&D productivity & innovation with AI

    • How Pfizer uses advanced analytics and AI to drive forwards pharmaceutical development
    • Use cases ranging from business process engineering and automation to insights from healthcare data and genomics
    • What are the key obstacles to AI implementation?
    GENOMICS & HEALTH
    16:00

    MyGeneRank: A digital platform for Next-Generation genetic studies

    • Building a fully digital ecosystem for community-based participatory genetics research: what are the societal benefits and how could this inspire a new generation of preventive health technology platforms? 
    • Linking genetic + digital health data for health and behavioral insights and understanding how lifestyle factors affect non-communicable diseases such as CHD
    • Implementing at-home diagnostics for those at high-risk of non-communicable disease through combined genetic & health data to enable doctors to prescribe and monitor patient centric personalized apps in realtime
    PRECISION MEDICINE
    16:00

    Viome – our moonshot of creating a world where chronic illness can truly be a matter of choice

    • Why human microbiome is influential if not outright responsible for most chronic diseases
    • Hear about the technology that enables us to analyze microbial ecosystems, biochemical activities and immune system responses with AI and modulate these activities with food and nutrition
    • How exponential technologies are now making it possible for consumers to get insights into their bodies and act on them to prevent  and reverse chronic conditions
    ARTIFICIAL INTELLIGENCE
    16:00

    Programmable biology: empowering the Pocketome

    • The design and engineering of molecular, cellular and population-based computation
    • Domain-specific languages for the specification of biological computation
    • Theories and applications of biological computation
    GENOMICS & HEALTH
    16:20

    Combining artificial intelligence and collective intelligence to democratize bioinformatics

    • Designing the future of bioinformatics thanks to the OMICtools community
    • How to find the right pipeline of tools thanks to AI-based decision-making solutions?
    • Making bioinformatics accessible without the need for advanced IT skills
    PRECISION MEDICINE
    16:20

    SPONSORSHIP AVAILABLE

    Do you have a solution you would like to share with our audience?
    Contact Michael Shackil now on: michael.shackil@terrapinn.com  or call at +1 646.619.1809
    ARTIFICIAL INTELLIGENCE
    16:20

    SPONSORSHIP AVAILABLE

    Do you have a solution you would like to share with our audience?
    Contact Michael Shackil now on: michael.shackil@terrapinn.com  or call at +1 646.619.1809

    AFTERNOON REFRESHMENTS

    17:10

    PLATINUM SPONSOR

    To speak and sponsor please contact Michael Shackil
     Michael.Shackil@terrapinn.com
    Panel discussion
    17:30

    Establishing modern enterprise architecture in a Pharmaceutical R&D division

    • Scale your R&D pipeline whilst enabling innovation
    • How to enable speed and agility alongside increasing business and IT efficiency and effectively 
    • Case study: How implementation efforts within IT infrastructure empower researchers
    Panel discussion
    18:00

    AI - The Ethical Debate

    • With unprecedented data sharing via the cloud we have been provided with vast data lakes at our fingertips. 
    • Harnessing meaning from this data is possible through AI. 
    • However, as AI advances we are unable to always disseminate why or how it has deduced meaning from the data.
    • With garbage in garbage out does AI become biased?
    Panel discussion

    Networking Cocktail Reception

    YOUNG TALENT IN AI AWARD 2018
    Proposed by our partners in the field, this award will be presented to the most innovative and impressive example of AI research in BioData
    last published: 12/Dec/17 23:25 GMT